Clinical trial Recruiting at 1 site Interventional Ages 20 to 50

ELDOA vs AIS for Median Nerve Mobility in Upper Limb Overuse

Official title: Elongation Longitudinal Decoaptation Ostéo-Articulaire Versus Active Isolated Stretching on Median Nerve Mobility and Pain in Patient With Upper Limb Overuse Syndrome

Run by University of Faisalabad · NCT07703332 · Data updated 2026-11-12

This trial tests whether ELDOA at the C5-C6 level or AIS better improves median-nerve mobility and reduces pain in adults with upper limb overuse syndrome.

Quick facts

Study typeInterventional
Ages20 Years to 50 Years
SexAll
Enrollment84 (estimated)
SponsorUniversity of Faisalabad
Academic / other
Locations1 site (Faisalabad, Punjab Province)
StatusRecruiting
StartedJuly 10, 2026
Main results expectedAugust 20, 2026
Study endsAugust 25, 2026
Registry record updatedJuly 14, 2026
Trial IDNCT07703332 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 20-50 with a clinical diagnosis of upper limb overuse syndrome and measurable median nerve involvement, lasting at least 3 months, not receiving recent neural mobilization therapy or major upper limb surgery.

Probably not a fit

Individuals with conditions that are not primarily median-nerve related or with contraindications to targeted neural interventions may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized clinical trial compares two physical therapy approaches for upper limb overuse syndrome: ELDOA targeting the C5-C6 segment and AIS to improve soft tissue elasticity and neural glide. Eighty-four adults aged 20-50 with a 3-month or longer history of symptoms will be enrolled and randomized equally. Outcomes will focus on changes in median nerve mobility and pain, using standard clinical measures. The study is conducted at a single site in Faisalabad, led by the University of Faisalabad, with participation limited to those not receiving recent neural-focused therapy or recent surgeries. No prior direct comparison between these methods exists in the literature to date.

Why it matters

Potential benefit: If successful, participants may experience improved nerve mobility and reduced pain, potentially enabling better function in daily activities.

How similar studies have gone: Direct comparative data between ELDOA and AIS are limited, making this head-to-head trial relatively novel in this specific context.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* All adult age group (20-50 years) patients with clinical symptoms and signs of upper limb overuse syndrome with median nerve were included in the study (Latif et al., 2022).
* Participants included individuals engaged in repetitive upper-limb activities, such as office workers, manual laborers, athletes and students, who demonstrated median nerve involvement associated with repetitive task performance (Descatha et al., 2017).
* Persistent pain in the upper limb, pain intensity score from 3-7 on the Numeric pain rating scale (NPRS), discomfort and functional limitations in daily activities, occupational tasks or recreational activities were deemed to be indications of eligibility for participation in the study (Hawker et al., 2011).
* Participants with persistent nature symptoms (3 months or more than 3 months) are included in the study to secure homogenous study population (Nicholas et al., 2019).
* Willing to give their informed consent and take part.

Exclusion Criteria:

* Trauma, surgery, fracture or dislocation of the upper limb in the last six months or less were excluded to minimize the possibility of studying the acute tissue healing on the results of this study (Cools et al., 2021).
* Other neurological conditions (e.g., peripheral or central nervous system disorders, systemic neuropathies, cervical radiculopathy, or other neurological disorders) were excluded for participation (Padua et al., 2020).
* The potential effect of rheumatologic or inflammatory musculoskeletal disorders (rheumatoid arthritis, lupus, or other systemic inflammatory diseases) on pain and functional status was also a reason for exclusion (Smolen et al., 2020).
* No corticosteroid uses or prior physical therapy within 3 months to reduce the potentially confounding effect of prior therapeutic interventions on study outcomes (Kolasinski et al., 2020).
* Participants were excluded from the study if they had any contraindications to manual therapy treatment that could affect the safety of the intervention (e.g., vascular, severe osteoporosis, malignancy, acute infection, other conditions) (Puentedura et al., 2012).

Where it's running

  • Dr . Rubina Zulfqar
    Faisalabad, Punjab Province, Pakistan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.